WO2002089690A2 - Dental composition for treating hypersensitive teeth - Google Patents

Dental composition for treating hypersensitive teeth Download PDF

Info

Publication number
WO2002089690A2
WO2002089690A2 PCT/US2002/013978 US0213978W WO02089690A2 WO 2002089690 A2 WO2002089690 A2 WO 2002089690A2 US 0213978 W US0213978 W US 0213978W WO 02089690 A2 WO02089690 A2 WO 02089690A2
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
dental composition
agent
tubules
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/013978
Other languages
English (en)
French (fr)
Other versions
WO2002089690A3 (en
Inventor
Benjamin D. Fitz
Kenneth J. Markowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Block Drug Co Inc
Original Assignee
Block Drug Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Block Drug Co Inc filed Critical Block Drug Co Inc
Priority to AU2002308581A priority Critical patent/AU2002308581A1/en
Priority to EP02769323A priority patent/EP1390004B1/en
Priority to BR0209368-5A priority patent/BR0209368A/pt
Priority to AT02769323T priority patent/ATE435053T1/de
Priority to JP2002586832A priority patent/JP3946644B2/ja
Priority to DE60232790T priority patent/DE60232790D1/de
Publication of WO2002089690A2 publication Critical patent/WO2002089690A2/en
Anticipated expiration legal-status Critical
Publication of WO2002089690A3 publication Critical patent/WO2002089690A3/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Definitions

  • the present invention relates to compositions and methods for the treatment of dental hypersensitivity.
  • Dentinal hypersensitivity is a temporary induced pain sensation produced when hypersensitive teeth are subjected to changes in temperature and/or pressure or to chemical action. Hypersensitivity may occur whenever the dentin of a tooth is exposed by attrition or abrasion, or when the tooth's finer root surface is exposed by periodontal disease. Dentin is a bone-like material in teeth that is usually covered by enamel above the gum line and cementum below the gum line. The enamel or cementum may be removed through decay, injury, disease or other causes, thereby exposing the dentin to external stimuli in the mouth. Dentin generally contains channels, called tubules, that allow material and energy transport between the exterior of the dentin and the interior of the tooth where the nerve is located.
  • hypersensitivity may be treated by making the nerve in the tooth less sensitive to stimuli, or by blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli.
  • tubule blocking agents include the following: charged polystyrene beads, U.S. Patent No. 5,211,939; apatite, U.S. Patent No. 4,634,589; a polyacrylic acid polymer having a typical molecular weight from about 450,000 to about 4,000,000, U.S. Patent No. 5,270,031; and certain clays, U.S. Patent No. 5,589,159. Still others have attempted to treat dentin sensitivity by inducing the growth of mineral inside the dentinal tubules. A further approach described in U.S.
  • Patent 5,735,942 to Litkowski and U.S. Patent 5,891,233 to Salonen et al. is the use of bioactive glass to treat tooth sensitivity.
  • these inventions suffer from problems of fluoride compatibility and these inorganic solids are abrasive materials.
  • compositions containing certain liposomes are effective in treating hypersensitivity.
  • the compositions of the present invention are unique in that they are capable of inducing mineral formulation in dentinal tubules thereby occluding the tubules.
  • the subject compositions are further unique in that, in addition to providing tubule blocking, the liposomes themselves have the capability to deliver nerve desensitizing agents, thereby also acting to reduce the excitability of the nerve to external stimuli.
  • the present invention relates to an orally acceptable formulation for the treatment of dentinal hypersensitivity containing liposomes capable of inducing mineral formation in the dentinal tubules and which may carry a further therapeutic agent, such as a desensitizing agent, for reducing the sensitivity of the nerve to external stimuli.
  • the present invention also encompasses methods for the treatment of dentinal hypersensitivity utilizing compositions containing certain liposomes.
  • the present invention provides a composition for treating hypersensitive teeth comprising a carrier suitable for oral health use and an effective amount of certain liposomes that have the capacity to induce mineral formation in the dentinal tubules thereby achieving tubule occlusion.
  • Liposomes are well known materials, as is their preparation from a wide variety of amphiphilic molecules. While liposomes have been utilized for a variety of applications in the health field, primarily as vehicles for various active substances, they have not been extensively used for dental preparations. In those instances where liposomes have been proposed for used in dental preparations, it has been necessary to utilize a "target molecule" in order for them to adhere to dental hard tissue, such as enamel and dentin.
  • the target functions like a tentacle that functions to anchor the liposome to dentin and enamel.
  • liposomes must be connected via chromium metal ions to another target molecule that has an affinity for hydroxy apatite.
  • the surface of the liposome is critical and it has been found in accordance with the present invention that the surface of the liposomes must be anionic.
  • the anionic surface of these materials induces mineral formation by acting as a mineral template that attracts soluble mineral ions that are naturally present in the dentin tubular fluid and saliva.
  • These liposome-surface-attracted soluble mineral ions precipitate from the dentin tubule fluid onto the liposome surface, which in turn acts to nucleate mineral growth in the fluid.
  • the mineral formed in the dentinal tubules will provide a massive insoluble plug, thereby restoring the tubules to their healthy, naturally impermeable state, blocking tubule fluid movement and insulating the dentinal nerves.
  • the plugging action acts to impede subsequent transmission of material energy and pressure gradients through the dentin, and may also retard the penetration of oral bacteria or the by-products of bacterial metabolism, an added benefit.
  • the liposomes of the present composition are prepared from salts of diolylphosphatidic acid (DOPA, Avanti® Polar Lipids, Inc.).
  • DOPA diolylphosphatidic acid
  • the liposome diameter should not be greater than about 2 microns, preferably from about 0.1 to 1.5 microns, most preferably about 0.5 micron.
  • the present invention provides a dentifrice composition for treating hypersensitive teeth comprising an effective amount of a mineral-inducing liposome wherein the liposome is a potassium salt of DOPA, having a diameter not greater than 0.5 microns.
  • the liposomes of the present invention provide a means of delivering additional agents, specifically nerve desensitizing agents into the dentinal tubules and releasing them therein in a controlled fashion. This is a significant advantage in that the overall effect of the subject preparations is enhanced by the action of two agents that function to treat dentinal hypersensitivity by two recognized mechanisms.
  • Such nerve desensitizing agents include, for example, potassium salts such as nitrate, bicarbonate, chloride, citrate, and oxalate and other intradental nerve agents, such as capsaicin and eugenol, and certain other desensitizing salts such as strontium salts, for example the chloride, calcium chloride and the like.
  • liposomes in accordance with the present invention possesses significant advantages over art-recognized inorganic treatments for biomineralization, such as disclosed in U.S. Patents Nos. 5,735,942 and 5,891,233.
  • the subject compositions are compatible with fluoride, can be prepared in an economically advantageous single-phase dentifrice tube and have no abrasivity.
  • the oral compositions of the present invention are typically formulated in the form of toothpastes or gel dentifrices to be brushed on the teeth, or in the form of mouthwashes.
  • the subject desensitizing agent can be formulated into a tooth powder, dentifrice, mouthwash, lozenge buccal adhesive patch, oral spray, coatings that adhere to the oral cavity, chewing gum and the like.
  • these delivery forms are prophetic, higher or lower amounts of these agents may be combined to achieve the desired effect.
  • the subject dentifrice compositions contain the liposomes as described herein in between about 0.1 and 20% by weight, preferably between about 3 and 10% by weight.
  • dentifrice compositions in the form of a paste or gel that comprises 5% by weight of DOPA liposomes.
  • the liposome may also be incorporated into other liposome membrane-compatible materials, which can be used to tailor the release characteristics of any materials that the liposomes may carry.
  • the lipsomes may also be used to control the rate of in-tubule liposome biodegradation and to control other aspects of liposome stability.
  • the subject formulations may contain additional ingredients typically incorporated into oral health care compositions. Suitable ingredients include, without intended limitation, abrasive polishing materials, sudsing agents, flavoring agents, humectants, binders, sweetening agents, and water.
  • Abrasives which may be used in the compositions of the invention include alumina and hydrates thereof, such as alpha alumina trihydrate, magnesium trisilicate, magnesium carbonate, aluminosilicate, such as calcined aluminum silicate and aluminum silicate, calcium carbonate, zirconium silicate, polymethylmethacrylate, powdered polyethylene, silica xerogels, hydrogels and aerogels and the like.
  • abrasive agents are calcium pyrophosphate, insoluble sodium metaphosphate, calcium carbonate, dicalcium orthophosphate, particulate hydroxyapatite and the like.
  • the abrasive may be present in an amount up to 70% by weight, preferably 1 to 70% by weight, more preferably from 10 to 70% by weight, particularly when the composition is formulated into a toothpaste.
  • Humectants contemplated for use in the subject compositions include polyols, such as glycerol, sorbitol, polyethylene glycols, propylene glycol, hydrogenated partially hydrolyzed polysaccharides and the like.
  • the humectants are generally present in amounts up to 80%, preferably 5 to 70% by weight for toothpaste formulations.
  • Thickeners suitable for use in the invention typically silica, may be present at a level from about 0.1 to 20% by weight.
  • Binders suitable for use in the compositions of the invention include hydroxyethyl cellulose, and hydroxypropyl cellulose, as well as xanthan gums, Iris moss and gum tragacanth.
  • Binders may be present in the amount from 0.01 to 10%.
  • Sweeteners suitable for use e.g. saccharin, may be present at levels of about 0.1% to 5%.
  • Fluoride sources as discussed above for delivering anti-caries benefit include those commonly used in oral health care compositions, such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride and cobalt ammonium fluoride and the like.
  • Preferred compositions in accordance with the present invention will include a fluoride source.
  • Fluoride ions are typically provided at a level up to 1500 ppm, preferably 50 to 1500 ppm, although higher levels up to about 3000 ppm may be used as well.
  • Surfactants such as a soap, anionic, nonionic, cationic, amphoteric and/or zwitterionic, may be present in amounts up to 15%, preferably 0.1 to 15%, more preferably 0.25 to 10% by weight.
  • Anionic and/or nonionic surfactants are most preferred, such as sodium lauryl sulfate, sodium lauroyl sarcosinate and sodium dodecylbenzene sulonate.
  • Suitable flavors are usually included in low amounts, such as from 0.01 to about 5% by weight, especially from 0.1% to 5%.
  • compositions in accordance with the present invention may, and preferably will, include antibacterial agents include, for example, phenolics and salicylamides, and sources of certain metal ions such as zinc, copper, silver and stannous ions, e.g. zinc, copper and stannous chloride, and silver nitrate.
  • antibacterial agents include, for example, phenolics and salicylamides, and sources of certain metal ions such as zinc, copper, silver and stannous ions, e.g. zinc, copper and stannous chloride, and silver nitrate.
  • Such agents in addition to other functional agents, including therapeutic agents and nutrients, may be incorporated into the liposomes themselves in accordance with the present invention.
  • Dyes / colorants suitable for oral health care compositions i.e. FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc.
  • Various other optional ingredients may also be included in the compositions of the invention such as preservatives, vitamins such as vitamins C and E, other anti-plaque agents such as stannous salts, copper salts, strontium salts and magnesium salts.
  • pH adjusting agents such as calcium glycerophosphate, sodium trimetaphosphate
  • anti-staining compounds such as silicone polymers, plant extracts and mixtures thereof.
  • polymers particularly anionic polymers, such as polycarboxylates or polysulfonates, or polymers containing both a carboxylate and a sulfonate moiety, phosphonate polymers or polyphosphates may be included.
  • the various substances mentioned above are conventional ingredients suitable for oral care compositions, e.g., toothpastes, gels, mouthwashes, gums, powders, etc. Except where otherwise noted, references to toothpastes are to be construed as applying to gels as well. Mouthwash forms, e.g. mouthwashes, oral rinses and similar preparations, may be formulated as well.
  • Such preparations typically comprise a water/alcohol solution, including a flavor component, humectant, sweetener, sudsing agent, and colorant.
  • Mouthwashes can include ethanol at a level of from 0 to 60%, preferably from 5 to 30% by weight.
  • the present invention provides a method for treating dentinal hypersensitvity comprising treating the teeth with a therapeutically effective amount of the compositions as described herein.
  • the method may consist of blocking, occluding, or sealing dentinal tubules with anionic liposomes having a diameter not greater than about two microns.
  • the method of the invention comprises providing via the liposomes of the subject compositions one or more additional therapeutic agents, preferably nerve desensitizing agents providing treatment for hypersensitvity via desensitization of the nerve as well.
  • at least one of the formulations and the liposomes may contain other functional agents, for example, nutritional, anti-caries, anti-bacterial and the like.
  • liposomes may be formulated to withstand dissolution for a long period of time and may also be formulated, regardless of dissolution, to release a substance contained therein over a predetermined period of time. Both of these art recognized techniques are incorporated within the scope of the present invention. Liposomes that resist dissolution over a considerable period of time are beneficial in providing sustained blockage of the tubules. By the same token, liposomes that would provide release of other therapeutic agents, particularly nerve desensitizers, over a period of at least several hours are beneficial in the combined therapeutic approach discussed above. Techniques for preparing liposomes that possess these characteristics of dissolution and release are known in the art and need not be detailed herein. Those of ordinary skill in the art will appreciate, however, that a dissolution and/or release profile will have to be established using conventional techniques for each given set of liposomes and one or more therapeutic agents.
  • a dentifrice composition in accordance with the present invention may be made by mixing the ingredients in any conventional manner, for example by creating a gel with the water and gelling agent and then adding the water soluble ingredients. Finally, a surfactant is added and the hydrophobic ingredients, including the liposomes, are then added with blending. The mixture is then packaged in a convention dentifrice container such as a tube, and applied to the surface of the teeth through conventional brushing, coating, painting or other direct or indirect application technique.
  • the apparatus includes a gas capillary tube mounted on a ruler or other measuring instrument. An air bubble is injected into the glass capillary tube. By measuring the displacement of the bubble as a function of time, fluid flow through the dentin disc can be measured.
  • an experimental dentifrice is applied to the external surface with a nylon brush. After a defined period of brushing, the experimental material is rinsed off, and the post-application hydraulic conductance is measured. In this fashion, the ability of various experimental materials both alone and as components of dentifrice systems can be tested for the ability to obstruct fluid flow in the dentinal tubules. The percent flow reduction induced by brushing with the experimental materials can be calculated.
  • Another method of evaluating the liposome's mineral-inducing capability of the liposome compositions of the present invention is to monitor the calcium depletion from a stimulated extra-cellular fluid (SBF, a solution having an ionic composition that is physiologically representative of blood plasma), upon introduction of liposomes.
  • SBF stimulated extra-cellular fluid
  • the SBF solution is metastable with respect to several solid mineral phases at room temperature.
  • the SBF sample containing added liposomes develops a precipitate, while the control sample without liposomes is entirely transparent.
  • One of two 40 mL samples of SBF received 0.5 mL of a 0.15% solution of anionic liposomes.
  • the sample receiving the liposomes had developed a precipitate, which was separated from the supernatant.
  • the untreated SBF solution and the supernatant were analyzed for calcium.
  • the initial SBF solution and the supernatant contained 65 ppm and 44 ppm calcium, respectively.
  • the free calcium of the SBF would be depleted by approximately 2.5 x 10 "3 ppm.
  • the actual depletion of calcium was 21 ppm. This level demonstrates that significant mineralization had taken place since the depreciation is significantly higher than would be expected from only surfaces association.
  • a desensitizing dentifrice in accordance with the invention may be made by combining the ingredients given below in accordance with accepted formulation techniques:
  • a desensitizing mouthwash in accordance with the invention may be made by mixing the ingredients given below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
PCT/US2002/013978 2001-05-03 2002-05-03 Dental composition for treating hypersensitive teeth Ceased WO2002089690A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2002308581A AU2002308581A1 (en) 2001-05-03 2002-05-03 Dental composition for treating hypersensitive teeth
EP02769323A EP1390004B1 (en) 2001-05-03 2002-05-03 Dental composition for treating hypersensitive teeth
BR0209368-5A BR0209368A (pt) 2001-05-03 2002-05-03 Composição dental para o tratamento de dentes hipersensìveis
AT02769323T ATE435053T1 (de) 2001-05-03 2002-05-03 Dentale zusammensetzung zur behandlung überempfindlicher zähne
JP2002586832A JP3946644B2 (ja) 2001-05-03 2002-05-03 過敏性の歯を治療するための歯の組成物
DE60232790T DE60232790D1 (de) 2001-05-03 2002-05-03 Dentale zusammensetzung zur behandlung überempfindlicher zähne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/848,138 2001-05-03
US09/848,138 US6416745B1 (en) 2001-05-03 2001-05-03 Dental composition for treating hypersensitive teeth

Publications (2)

Publication Number Publication Date
WO2002089690A2 true WO2002089690A2 (en) 2002-11-14
WO2002089690A3 WO2002089690A3 (en) 2003-11-20

Family

ID=25302447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013978 Ceased WO2002089690A2 (en) 2001-05-03 2002-05-03 Dental composition for treating hypersensitive teeth

Country Status (8)

Country Link
US (1) US6416745B1 (enExample)
EP (1) EP1390004B1 (enExample)
JP (1) JP3946644B2 (enExample)
AT (1) ATE435053T1 (enExample)
AU (1) AU2002308581A1 (enExample)
BR (1) BR0209368A (enExample)
DE (1) DE60232790D1 (enExample)
WO (1) WO2002089690A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2362543C1 (ru) * 2007-12-12 2009-07-27 Закрытое Акционерное Общество "Лиэп" Дентальная липосомальная композиция и зубная паста, включающая указанную липосомальную композицию
WO2024074664A1 (en) * 2022-10-06 2024-04-11 Haleon UK IP Limited Dentifrice composition

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416745B1 (en) * 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth
AU2002331481B2 (en) * 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US6814794B2 (en) * 2002-11-06 2004-11-09 Ultradent Products, Inc. Temporary dental cements having reduced tooth sensitivity
US20040146831A1 (en) * 2003-01-23 2004-07-29 Kerrhawe Sa Unit dose delivery system for dental sensitivity product
US20040146464A1 (en) * 2003-01-23 2004-07-29 Bernstein Joel E. Compositions and method for daily tooth and gum care
JP2006518744A (ja) * 2003-02-21 2006-08-17 ローディア インコーポレイティド 抗感受性、抗カリエス、抗しみ、抗歯垢、ウルトラマイルド口腔衛生物質
EP1776083A4 (en) * 2004-07-02 2010-06-02 Discus Dental Llc SENSITIVITY-RELATED TOOTH COMPOSITIONS
US20080045575A1 (en) * 2004-12-29 2008-02-21 Van Dyke Thomas E Delivery of H2 Antagonists
US20070258916A1 (en) * 2006-04-14 2007-11-08 Oregon Health & Science University Oral compositions for treating tooth hypersensitivity
CN101938981A (zh) * 2008-02-08 2011-01-05 高露洁-棕榄公司 组合物和装置
US20100047742A1 (en) * 2008-08-25 2010-02-25 Pitcock Jr William Henry Tubule-blocking silica materials for dentifrices
US8905760B2 (en) * 2008-11-04 2014-12-09 Duane C. Keller Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations
US8956161B2 (en) 2008-11-04 2015-02-17 Duane C Keller Article and method for controlling oral-originated systemic disease
CA2742367A1 (en) * 2008-11-10 2010-05-14 Colgate-Palmolive Company Shelf stable capsules
TWI469795B (zh) * 2009-04-01 2015-01-21 Colgate Palmolive Co 防止過敏和促進再礦化之雙作用牙劑組成物
US20110206749A1 (en) * 2010-02-19 2011-08-25 J.M. Huber Corporation Silica materials for reducing oral malador
US8658139B1 (en) 2010-02-27 2014-02-25 Squigle, Inc. Prevention and treatment of oral diseases
US20110236444A1 (en) * 2010-03-25 2011-09-29 Darsillo Michael S Antimicrobial Silica Composites
US9084902B2 (en) 2010-06-30 2015-07-21 Mcneil-Ppc, Inc. Non-alchohol bioactive essential oil mouth rinses
US20120003162A1 (en) 2010-06-30 2012-01-05 Mcneil-Ppc, Inc. Methods of Preparing Non-Alcohol Bioactive Esential Oil Mouth Rinses
US8591229B2 (en) 2010-12-16 2013-11-26 Duane C. Keller Devices and methods for creating a positive pressure environment for treatment of oral biofilms associated with periodontal disease
BR112016006064B1 (pt) * 2013-09-19 2020-07-07 Allovate, Llc kit para terapia da mucosa oral, método para formular uma composição de dentífrico, e, uso de um kit para terapia da mucosa oral
EP3217952B9 (en) 2014-11-11 2019-09-04 Johnson & Johnson Consumer Inc. Amino acid derivatives and their uses
RU2730515C2 (ru) 2014-11-11 2020-08-24 Джонсон энд Джонсон Консьюмер Инк. Производные аминокислот и их использование
JP6732776B2 (ja) 2015-02-26 2020-07-29 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. 有機酸の組み合わせを含む組成物
US9326925B1 (en) 2015-02-26 2016-05-03 Johnson & Johnson Consumer Inc. Compositions comprising combinations of organic acids
US9326924B1 (en) 2015-02-26 2016-05-03 Johnson & Johnson Consumer Inc. Compositions comprising combinations of organic acids
US9974722B2 (en) 2016-10-20 2018-05-22 Johnson & Johnson Consumer Inc. Reduced-ethanol mouth rinse formulations
US20190175487A1 (en) 2017-12-07 2019-06-13 Johnson & Johnson Consumer Inc. Oral Care Compositions
US20190175486A1 (en) 2017-12-07 2019-06-13 Johnson & Johnson Consumer Inc. Oral Care Compositions
WO2020021481A1 (en) 2018-07-27 2020-01-30 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating the eye
US11166997B2 (en) 2018-07-27 2021-11-09 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
JP2021532121A (ja) 2018-07-27 2021-11-25 ジョンソン・アンド・ジョンソン・サージカル・ビジョン・インコーポレイテッド 眼を治療するための組成物及び方法
CN109010240A (zh) * 2018-10-25 2018-12-18 大连丹特生物技术有限公司 一种缓解牙齿敏感的药用组合物及其制备方法和应用
US20210023153A1 (en) 2019-07-23 2021-01-28 Johnson & Johnson Consumer Inc. Compositions and Methods for Treating the Oral Cavity
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863006A (en) 1973-01-29 1975-01-28 Milton Hodosh Method for desensitizing teeth
US4767615A (en) 1984-05-03 1988-08-30 Technology Unlimited, Inc. Dental therapy by vesicle delivery
US4634589A (en) 1984-05-18 1987-01-06 Wurttembergische Parfumerie-Fabrik Gmbh Dentifrice for hypersensitive teeth
EP0429442B1 (en) * 1988-08-22 1993-12-29 DDS Technology, Limited Dental therapy by vesicle delivery
US5104661A (en) * 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition
GB9022298D0 (en) * 1990-10-15 1990-11-28 Unilever Plc Treatment composition
FR2676362B3 (fr) * 1991-05-17 1993-08-13 Oreal Procede pour accroitre l'activite d'au moins un actif dans une composition a usage cosmetique et/ou dermopharmaceutique et composition pour la mise en óoeuvre dudit procede.
US5211939A (en) 1991-09-13 1993-05-18 Gillette Canada Method for desensitizing teeth
US5270031A (en) 1991-12-20 1993-12-14 Block Drug Company Inc. Dentinal desensitizing compositions
DE4306475A1 (de) * 1993-03-02 1994-09-08 Ensenat Pedro Gonzalez Liposomen, enthaltend Chlorhexidindiacetat oder Chlorhexidindigluconat
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
CA2187355C (en) * 1994-04-08 2009-10-13 Richard L. Dunn An adjunctive polymer system for use with medical device
FI104881B (fi) 1994-10-06 2000-04-28 Bioxid Oy Uusien bioaktiivista piipitoista lasia sisältävien koostumusten valmistusmenetelmä
US5589159A (en) 1995-04-11 1996-12-31 Block Drug Company Inc. Dispersible particulate system for desensitizing teeth
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US5735942A (en) 1996-02-07 1998-04-07 Usbiomaterials Corporation Compositions containing bioactive glass and their use in treating tooth hypersensitivity
US6045823A (en) * 1996-09-19 2000-04-04 Dragoco Gerberding & Co. Ag Process for producing solid anhydrous composition, and pharmaceutical and cosmetic products comprising same
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US5922332A (en) * 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
WO1999059535A1 (en) * 1998-05-15 1999-11-25 Unilever Plc Oral composition comprising capsules
DE19922193B4 (de) * 1999-05-12 2004-12-02 Sonnenberg, Frank, Dipl.-Biol. Wasserlösliches Konzentrat, bestehend aus ätherischen Ölen mikroverkapselt in einem Liposomensystem, ein Verfahren zu seiner Herstellung und die Verwendung
WO2002015809A2 (en) * 2000-08-21 2002-02-28 Block Drug Company, Inc. Dental composition for hypersensitive teeth
US6416745B1 (en) * 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2362543C1 (ru) * 2007-12-12 2009-07-27 Закрытое Акционерное Общество "Лиэп" Дентальная липосомальная композиция и зубная паста, включающая указанную липосомальную композицию
WO2024074664A1 (en) * 2022-10-06 2024-04-11 Haleon UK IP Limited Dentifrice composition

Also Published As

Publication number Publication date
JP2004525190A (ja) 2004-08-19
JP3946644B2 (ja) 2007-07-18
EP1390004A2 (en) 2004-02-25
BR0209368A (pt) 2004-06-08
WO2002089690A3 (en) 2003-11-20
EP1390004B1 (en) 2009-07-01
ATE435053T1 (de) 2009-07-15
US6416745B1 (en) 2002-07-09
DE60232790D1 (de) 2009-08-13
AU2002308581A1 (en) 2002-11-18
EP1390004A4 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
US6416745B1 (en) Dental composition for treating hypersensitive teeth
AU2001296802B2 (en) Anhydrous dentifrice formulations for the delivery of incompatible ingredients
EP2648679B1 (en) Dentifrice compositions containing calcium silicate and a basic amino acid
US20030215401A1 (en) Dental composition for hypersensitve teeth
AU2001296802A1 (en) Anhydrous dentifrice formulations for the delivery of incompatible ingredients
EP2648677B1 (en) Dentifrice compositions containing calcium silicate
US20070258916A1 (en) Oral compositions for treating tooth hypersensitivity
TW201204402A (en) Oral care composition
CA2924229A1 (en) Dentifrice composition comprising sintered hydroxyapatite
US5885551A (en) Treatment for dentinal hypersensitivity
JP2000154127A (ja) 口腔用組成物
US20020041852A1 (en) Dental composition for hypersensitive teeth
JPS6011412A (ja) 口腔衛生組成物及びその製法
US20070059257A1 (en) Dentinal composition for hypersensitive teeth
CA2979333C (en) Oral care compositions and methods of using the compositions
WO2002015857A1 (fr) Composition orale
NZ214807A (en) Dentifrice or mouthwash containing hydrogen citrate ions and fluoride ions
JP2002265341A (ja) 口腔組成物
EP2956112B1 (en) Dental composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002586832

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002769323

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002769323

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642